N-ethyl-m-toluidine appears as a light amber liquid. Less dense than water and insoluble in water. Vapors heavier than air. Produces toxic oxides of nitrogen during combustion. Used to make other chemicals.
Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patent can swallow, has a strong gag reflex, and does not drool. Administer activated charcoal ... . /Aniline and related compounds/
Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious. Monitor cardiac rhythm and treat arrhythmias as necessary... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Administer 1% solution methylene blue if patient is symptomatic with severe hypoxia, cyanosis, and cardiac compromise not responding to oxygen. ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Consider vasopressors if hypotensive with a normal fluid volume. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation... . /Aniline and related compounds/
N-ethyl-meta-toluidine (CAS # 102-27-2) was evaluated for acute oral toxicity in Sprague-Dawley rats (5/sex/group) fed doses of 100, 500, 750, and 1000 mg/kg once by oral gavage. Treatment was associated with mortality consistent with an oral LD50 (with 95% confidence limits) of 787 (585-1058) mg/kg. Only animals of 750 and 1000 mg/kg doses died and all, but 3 rats deceased on Days 4, 5, and 7, died on Days 2 and 3 post-gavage. All surviving rats gained weight. Clinical toxicity was characterized by cyanosis in all but 2 rats of 100 mg/kg doses and 1 of a 500 mg/kg dose. Other pharmacotoxic signs noted in more than 1 treated rat included hypoactivity, wet inguinal and/or discolored fur, discolored paws, redness about the nose, discoloration about the mouth, rough hair coat, dyspnea, diarrhea, ataxia, coldness to touch, dark urine, vocalization, pallor, and dyspnea. Necropsy of decedent rats and rats surviving 14-day post-gavage observation identified no gross pathology among animals of 100 or 500 mg/kg doses. Among rats of higher doses (750, 1000 mg/kg), gross lesions included dark brown, red, and/or mottled lungs; dark brown and/or small spleen; dark brown or pale liver; dark brown heart, red fluid-filled urinary bladder, dark brown kidney, and thymic foci.
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
Homogeneous Catalytic Hydrogenation of Amides to Amines
作者:Jacorien Coetzee、Deborah L. Dodds、Jürgen Klankermayer、Sandra Brosinski、Walter Leitner、Alexandra M. Z. Slawin、David J. Cole-Hamilton
DOI:10.1002/chem.201204270
日期:2013.8.12
Hydrogenation of amides in the presence of [Ru(acac)3] (acacH=2,4‐pentanedione), triphos [1,1,1‐tris‐ (diphenylphosphinomethyl)ethane] and methanesulfonic acid (MSA) produces secondary and tertiary amines with selectivities as high as 93 % provided that there is at least one aromatic ring on N. The system is also active for the synthesis of primary amines. In an attempt to probe the role of MSA and
在[Ru(acac)3 ](acacH = 2,4-戊二酮),三[[1,1,1-三(二苯基膦甲基)乙烷]]和甲磺酸(MSA)的存在下进行酰胺加氢生成仲胺和叔胺如果在N上至少有一个芳环,则其选择性高达93%。该系统对伯胺的合成也具有活性。为了探索MSA的作用和反应机理,已经从[Ru(acac)3 ],三醇和MSA或[RuX(OAc)(triphos)]的反应中制备了一系列甲磺酸钠络合物。 (X = H或OAc)或[RuH 2(CO)(triphos )]与MSA。晶体学表征复合物包括:[茹(OAC-κ 1 O)2(H 2O)(triphos)],[Ru(OAc‐κ 2 O,O')(CH 3 SO 3 ‐κ 1 O)(triphos )],[Ru(CH 3 SO 3‐ κ 1 O)2(H 2 O)(三膦)]和[孺2(μ-CH 3 SO 3)3(三磷酸)2 ] [CH 3 SO 3 ],而其他复合物,例如[茹(OAC-κ
Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
申请人:——
公开号:US20020120011A1
公开(公告)日:2002-08-29
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound:
1
[EN] UREA DERIVATIVES OF AMPHOTERICIN B DERIVED FROM SECONDARY AMINES<br/>[FR] DÉRIVÉS D'URÉE DE L'AMPHOTÉRICINE B DÉRIVÉE D'AMINES SECONDAIRES
申请人:UNIV ILLINOIS
公开号:WO2016112243A1
公开(公告)日:2016-07-14
Provided are certain urea derivatives of amphotericin B (AmB) having improved therapeutic index compared to AmB. The compounds of the invention are less toxic than AmB and are useful to treat fungal infections. In certain embodiments the urea derivative of AmB is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: wherein, independently for each occurrence: R represents methyl, ethyl, propyl, or isopropyl; R' represents methyl, ethyl, propyl, or isopropyl; or R and R', taken together with the nitrogen atom to which they are attached, represent a radical of a cyclic secondary amine. Also provided are methods for making the urea derivatives of AmB.
A new entry to the imidazo[4,5-<i>d</i>]pyrimidine system. The reaction of 1,3-dimethyl-6-aminouracil with<i>N,N</i>-dimethyldichloromethyleniminium chloride (phosgeniminium chloride) and trimethylsilyl azide, a novel and convenient “one pot” synthesis of 8-<i>N</i>-arylaminotheophyllines (2-<i>N</i>-arylamino-4,6-dimethylimidazo[4,5-<i>d</i>]pyrimidine-(4H,6H)-5,7-diones), starting from 1,3-dimethyl-6-aminouracil
作者:Bruno Kokel
DOI:10.1002/jhet.5570310515
日期:1994.9
5-d]pyrimidine-(4H,6H)-5,7-diones) 17 through reaction successively, with phosgeniminium chloride (N,N-dimethyldichloromethyleniminium chloride) (1a), trimethylsilyl azide (4) and arylamines. Starting with the synthesis of the N,N-dimethyl(1,3-dimethyl-4-aminouracil-5-yl)chloromethyleniminium chloride (amide chloride) 3 this new route to the imidazo[4,5-d]pyrimidine skeleton was shown to proceed via the
1,3-二甲基-6-氨基尿嘧啶2转化为各种8- N-芳基氨基茶碱(2- N-芳基氨基-4,6-二甲基咪唑并[4,5- d ]嘧啶-(4 H,6 H)-5,通过与光气氯化亚氨基氯化铵(N,N-二甲基二氯甲基亚甲基氯化铵)(1a),叠氮化三甲基甲硅烷基(4)和芳基胺相继反应而形成7-二酮)17。从合成N,N-二甲基(1,3-二甲基-4-氨基尿嘧啶-5-基)氯甲基亚氯化铵(酰胺氯化物)3开始,这是一条新的制备咪唑并[4,5- d已显示]嘧啶骨架是通过形成非常不稳定的N,N-二甲基-(1,3-二甲基-4-氨基尿嘧啶-5-基)叠氮基甲基氯化亚铵(酰胺叠氮化物)(8)形成的,该反应会原位进行重排成4-氨基-5-(氯甲酰胺-1'-基)尿嘧啶和/或类型10的相关化合物的可能性很大。根据反应条件,证明后者也是8-二甲基氨基茶碱11的非常好的前体。
[EN] THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES<br/>[FR] COMPOSÉS DE THIÉNOPYRROLE ET LEURS UTILISATIONS À TITRE D'INHIBITEURS DE LUCIFÉRASES DÉRIVÉES D'OPLOPHORUS
申请人:PROMEGA CORP
公开号:WO2016210294A1
公开(公告)日:2016-12-29
Thienopyrrole compounds that may inhibit Oplophorus -derived luciferases are disclosed, as well as compositions and kits comprising the thienopyrrole compounds, and methods of using the thienopyrrole compounds.